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Serotonin modulates a variety of processes throughout the brain, but it is perhaps
best known for its involvement in the etiology and treatment of depressive disorders.
Microdialysis studies have provided a clear picture of how ambient serotonin levels
fluctuate with regard to behavioral states and pharmacological manipulation, and
anatomical and electrophysiological studies describe the location and activity of serotonin
and its targets. However, few techniques combine the temporal resolution, spatial
precision, and chemical selectivity to directly evaluate serotonin release and uptake.
Fast-scan cyclic voltammetry (FSCV) is an electrochemical method that can detect minute
changes in neurotransmitter concentration on the same temporal and spatial dimensions
as extrasynaptic neurotransmission. Subsecond measurements both in vivo and in brain
slice preparations enable us to tease apart the processes of release and uptake. These
studies have particularly highlighted the significance of regulatory mechanisms to proper
functioning of the serotonin system. This article will review the findings of FSCV
investigations of serotonergic neurotransmission and discuss this technique’s potential
in future studies of the serotonin system.
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INTRODUCTION
The neurotransmitter serotonin [also called 5-
hydroxytryptamine (5-HT)] can be found in nearly every
region of the central nervous system. Its functions are as diverse
as the areas they innervate, and it is a complex component
of many psychiatric disorders. This pervasive involvement in
brain-wide neurocircuitry is supported by an exceptionally large
family of receptors whose collective functional scope enables the
multifarious actions of serotonin throughout the brain (Barnes
and Sharp, 1999). Much of our knowledge about serotonin
comes from studies investigating its actions via these receptors,
which remain the target of many pharmacotherapies involving
serotonergic signaling. However, the release and uptake dynamics
of serotonin precipitate its downstream effects, and exploring
how these dynamics are modulated has provided key insights to
the serotonin system and its therapeutic potential.
A number of techniques have been used to characterize sero-
tonin signaling in the brain. In vivo microdialysis has provided
key insights into natural and pharmacologically-induced fluc-
tuations in ambient extracellular levels of serotonin. However,
even recent advancements inmicrodialysis sampling rates provide
markedly lower temporal resolution than required to examine
individual release and uptake events (Schultz andKennedy, 2008).
Electrophysiological measurements can infer some properties of
neurotransmitter release by measuring postsynaptic response,
and this method works well for neurotransmitters like gluta-
mate and GABA, whose ligands effect instantaneous changes in
ionic current or membrane potential. However, most serotonin
receptors in the brain are G-protein coupled and activate intra-
cellular cascades over time periods of 400ms or more, resulting in
postsynaptic effects that are too slow or heterogeneous to reveal
information about small, fast changes in concentration. Rigorous
characterization of serotonin signaling requires a technique that
operates on the same temporal and spatial scales as its release and
uptake processes.
Electroanalytical techniques, which combine chemical selec-
tivity with high temporal resolution, are often used in brain tissue
to monitor small, fast changes in neurotransmitter concentra-
tions concurrent with release and uptake. Serotonin signaling has
been studied using several electroanalytical techniques, includ-
ing differential pulse voltammetry and chronoamperometry [for
a review, see Stamford (1985)]. Among these techniques, fast-scan
cyclic voltammetry (FSCV) is the best combination of temporal
and chemical sensitivity for measuring endogenous changes in
serotonin concentration in brain tissue. This article will review
the findings of voltammetric studies and discuss their contribu-
tion to current understanding of the mechanisms modulating
serotonin release and uptake.
FAST-SCAN CYCLIC VOLTAMMETRY OF SEROTONIN
FSCV is an electrochemical technique that detects changes in
endogenous neurotransmitter levels rapidly enough to distin-
guish release and uptake events in brain tissue. The monoamine
neurotransmitters dopamine, norepinephrine, and serotonin are
well-suited to voltammetric detection because they oxidize pre-
dictably and at low potentials. To evaluate changes in neurotrans-
mitter concentration, FSCV measures the current generated by
the oxidation of a neurotransmitter. Oxidation is driven by a
potential waveform applied to a carbon-fiber sensor. The current
generated is proportional to the concentration of analyte at the
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carbon surface, so the current-to-concentration relationship can
be quantified by calibrating microelectrodes in authentic stan-
dards before or after experimental use. Chemical selectivity, or
the ability to identify the neurotransmitter being measured, is
facilitated by analyzing the plot of generated current vs. applied
potential. This current-voltage curve is termed the cyclic voltam-
mogram. Monoamines oxidize and reduce at predictable poten-
tials, and their cyclic voltammograms have a characteristic shape
that is easy to recognize. An example of a voltage waveform, cyclic
voltammograms, and in vitro calibration is shown in Figure 1.
The “fast-scan” in the technique’s name refers to the potential
waveform, which is applied rapidly and repeatedly, producing
FIGURE 1 | In vitro calibration of microelectrodes. (A) Voltage potential
waveform, described by Jackson et al. (1995), for detection of serotonin. (B)
Cyclic voltammograms (current-voltage curves) obtained for known
concentrations of serotonin injected into a flow cell apparatus. The
concentration (right) and its corresponding oxidation current amplitude (left
axis) are noted by dashed lines. (C) Maximal oxidation current vs.
concentration of serotonin. The data are fit to a linear regression (black
line), the slope of which gives a calibration factor for serotonin measured at
these electrodes.
up to 10 cyclic voltammograms per second. The carbon-fiber
microelectrode sensors used in FSCV have small dimensions
(5× 100µm), and this small size enables sampling from as few
as 100 synapses at a time, with the electrode targeted to a discrete
brain region. Thus, FSCV is a technique for which temporal and
spatial scales of data collection are compatible with monitoring
neurotransmission.
BRAIN REGIONS WITH MEASURABLE SEROTONIN RELEASE
In brain slices, changes in serotonin concentration can be evoked
using local electrical stimulation in brain regions containing sero-
tonergic neurons or their axonal projections. The dorsal raphe
nucleus (DRN), a tiny hub in the core of the medulla, contains
the majority of serotonin-producing neurons that send ascending
projections into the brain. Voltammetric measurements detect
serotonin efflux from both axonal and somatodendritic sites in
this region because a subset of serotonergic neurons synapse
locally. Although axonal serotonin release is prevalent through-
out the central nervous system, experiments employing FSCV
are typically constrained to brain regions dense with serotonergic
terminals and limited interference from other neurotransmit-
ters and metabolites. These studies predominantly take place in
the substantia nigra, a midbrain region composed of the pars
compacta, packed with dopamine-synthesizing neurons, and the
pars reticulata (SNr), a networked relay region that includes
the densest serotonergic projections from the DRN to any fore-
brain region (9× 106 sites per mm3) (Moukhles et al., 1997). In
the SNr, serotonin is the predominant electroactive neurotrans-
mitter evoked by electrical stimulations, frequently observed in
the absence of somatodendritic dopamine release (Cragg et al.,
1997). However, Moukhles et al. (1997) reported that serotoner-
gic processes form synaptic junctions at a high rate in the SNr
than any other brain region. It should be considered, therefore,
that serotonin dynamics described in this region may be dis-
similar to the dynamics in other brain regions, including the
cerebral cortex, neostriatum, and hippocampus, where a majority
of serotonin terminals form non-junctional synapses (Descarries
et al., 1990). Serotonin efflux has also been described using
FSCV in brain slices containing the suprachiasmatic nucleus
(SCN) and ventral lateral geniculate nucleus (vLGN), hypotha-
lamic and thalamic areas with similarly robust serotonergic
innervation.
Serotonin measurements in in vivo FSCV experiments have
taken place exclusively in the SNr. Thick vasculature and
meninges above the DRN make targeting this region in the
intact brain with a fragile carbon-fiber microelectrode difficult.
Other serotonergic regions of interest, such as the hippocampus
and prefrontal cortex, have not been explored due to significant
chemical interference from other monoamines. However, recent
advancements in neuronal stimulation technology may help cir-
cumvent this problem, and these potential future directions will
be discussed in more detail in the conclusion of this article.
ELECTROCHEMICAL IDENTIFICATION
Electrochemical methods, including FSCV, lack absolute chemical
specificity. Some chemical species, particularly those with similar
structure, can interfere with detection of the desired substance
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by oxidizing at similar or identical potentials. Therefore,
voltammetric measurements rely on five criteria for identification
of endogenously released substances: First, cyclic voltammograms
obtained under experimental conditions must have high corre-
lation with cyclic voltammograms of the authentic compound.
Second, presence of the neurotransmitter must be validated by
independent chemical identification, such as microdialysis, tis-
sue content analysis, or radioligand binding in the targeted brain
region. The third criterion requires precise anatomical posi-
tioning of the sensor into the brain region of interest. Fourth,
observed release should follow known physiological properties for
the neurotransmitter and target brain region. Finally, identifica-
tion of the released substance is dependent on pharmacological
validation.
O’Connor and Kruk (1991a) systematically addressed the
criteria for electrochemical validation in the first published
report of endogenous serotonin measured in rat brain slices
using FSCV (O’Connor and Kruk, 1991a). The cyclic voltam-
mogram obtained from electrically-evoked serotonin is highly
correlated to the one obtained after adding known concentra-
tions of serotonin to the bath solution. Stimulation trains (500ms
in duration) elicited transient flux in serotonin levels in the
DRN, where serotonin-synthesizing neurons are located, and
SCN, a region dense in serotonin projections from the DRN
(Fuxe, 1965). The evoked concentrations measured in both brain
regions was completely and reversibly abolished by removal of
calcium from the buffer solution or addition of sodium-channel
blocker tetrodotoxin, complying with known physiological prop-
erties of exocytotic release. RO 4-1284, an irreversible vesic-
ular monoamine transporter 2 (VMAT2) inhibitor, attenuated
release, confirming that observed release was vesicular in nature.
Inhibition of monoamine oxidase (MAO) had no effect on stim-
ulated efflux, ruling out interference from serotonin’s metabolite,
5-HIAA. Finally, the clearance rate of serotonin in the DRN
and SCN could be decreased after application of citalopram, a
selective serotonin uptake inhibitor, but not by benztropine, a
norepinephrine uptake inhibitor, to bath solution. Similar pro-
cedures validate the identity of serotonin detected in subsequent
experiments by this and other groups.
Bunin and Wightman (1998) later investigated an aspect of
serotonin’s physiological release properties that had not been
addressed by initial voltammetric characterizations. The dimen-
sions of carbon-fiber microelectrodes are considerably larger
than the synaptic cleft into which neurotransmitters are released
(Figure 2). Consequently, FSCV detects extracellular, not intrasy-
naptic, changes in concentration, and its measurements are lim-
ited to the neurotransmitter concentration that diffuses into the
extrasynaptic space following release. A number of neuromod-
ulators diffuse beyond the synaptic space to reach their recep-
tors and transporters in a process called volume transmission
(Fuxe et al., 2010), and prior evidence from non-voltammetric
techniques implicated serotonin as a volume neurotransmit-
ter. Ultrastructural studies of serotonergic terminals throughout
the brain suggest that they form predominantly non-junctional
synapses (Chazal and Ralston, 1987). This terminal architec-
ture, together with reports that expression of serotonin trans-
porters and receptors occurs primarily on extrasynaptic regions of
FIGURE 2 | Illustration of a carbon-fiber microelectrode in SNr. Scaling
of the microelectrode to in situ serotonergic fibers (gray) and uptake sites
(yellow) is a representation based on Moukhles et al. (1997).
neuronal processes (Kia et al., 1996; Zhou et al., 1998), is indica-
tive of volume transmission. In light of this information, Bunin
andWightman (1998) hypothesized that electrically-evoked sero-
tonin should reach the extracellular space via diffusion, without
buffering from uptake and receptor binding sites. This was found
to be the case for both somatodendritic and terminal release,
where the concentration of serotonin evoked per stimulation
pulse during 20-pulse trains was equivalent to the concentration
evoked by a single pulse (Bunin andWightman, 1998). Therefore,
the authors concluded that serotonin concentrations measured by
voltammetry reflect physiological volume transmission from the
synapse to its extrasynaptic targets.
TECHNICAL CONSIDERATIONS
Since O’Connor and Kruk’s first report of voltammetric detec-
tion of serotonin, several modifications have been implemented
to adapt and improve the use of FSCV for novel applications.
The voltage potential waveform (−1 to +1.4 to −1) used by
the Stamford and Kruk labs, as well as others, in serotonin
studies cited throughout this review was adjusted by Jackson
et al. (1995) to improve temporal resolution. This modification
to an N-shaped waveform, which scans from +0.2 to +1.0 to
−0.1 back to +0.2 (Figure 1A), was designed to reduce sero-
tonin adsorption to the electrode surface, as this slows electrode
response times. It also avoids fouling reactions of serotonin’s
oxidative and reductive byproducts, improving electrode sensi-
tivity and stability over time (Jackson et al., 1995). The modified
waveform’s improvement enhanced electrode response times and
enabled more accurate measurements of release and uptake rates,
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facilitating closer examination of the kinetic parameters of sero-
tonin release.
Improvement of carbon-fiber microelectrode sensors has been
another ongoing adaptation to voltammetric measurements of
serotonin. Brazell et al. (1987) first reported that dip-coating a
carbon-fiber microelectrode in Nafion, a cation-selective poly-
mer, improves serotonin and dopamine detection (Brazell et al.,
1987; Jackson et al., 1995). Nafion enhances serotonin detection
in two ways: first, by directly increasing the electrode’s sensitiv-
ity to (positively-charged) serotonin, and second, by reducing
its sensitivity to interfering anionic species such as uric acid
and serotonin’s metabolites. Years later, the success of the first
in vivo voltammetric measurements of endogenous serotonin
concentrations in a rat owe their success to the enhanced sensitiv-
ity and temporal resolution facilitated by Nafion-coated sensors
and the modified voltage potential waveform (Hashemi et al.,
2009).
Many labs continued their investigations of serotonin release
without adopting either modification. Because each study reports
on electrically-evoked changes in serotonin concentration, which
are derived from in vitro calibrations, comparing findings
between labs is not considered an issue within this review. It is
important to note that these calibrations do not take into account
the deleterious effects of electrode fouling that may be appre-
ciably different over the course an experiment depending on the
waveform used. Regardless of waveform choice, however, demon-
stration of a linear relationship between concentration applied
and the current evoked establish the suitability of a waveform for
stable detection of serotonin.
ELECTRICAL STIMULATION
Many of the optimal electrical stimulation parameters for evok-
ing somatodendritic and terminal serotonin in brain slices are
consistent with previously established physiological principles.
Serotonergic fibers are not myelinated and, like other unmyeli-
nated fibers, are maximally excited by wider stimulation pulse
widths, up to 2ms in length (Anden et al., 1967; Merrill et al.,
1978; Millar et al., 1985; Bunin et al., 1998). The amplitude
of evoked serotonin concentration is also strongly dependent
on increases in stimulation intensity (up to 380µA) and num-
ber of pulses in a stimulation train. Maximal release amplitudes
are also positively correlated with increasing frequency, up to
100Hz (O’Connor and Kruk, 1991b; Iravani and Kruk, 1997;
Bunin andWightman, 1998), although a detailed investigation by
John et al. (2006) found that electrically-evoked concentrations
were less sensitive to stimulation frequencies above 30Hz (John
et al., 2006). These constrained ranges of frequency dependence
could reflect limitations in vesicular availability, but Aghajanian
et al. (1990) has posited that processes in terminal regions
store enough serotonin to sustain long, high frequency release
(Aghajanian et al., 1990). Although serotonergic neurons are typ-
ically thought to fire at a rate of 0.5–5Hz, burst-firing in the
DRN has been measured at a rate of 100Hz (Aghajanian et al.,
1978; Vandermaelen and Aghajanian, 1983; Hajos et al., 1995).
Differences in the range of frequency sensitivity between stud-
ies may therefore reflect dynamic, physiological fluctuations and
could point to yet another regulatory component within the
serotonin system. Future investigation of the mechanisms influ-
encing frequency dependence would be an interesting addition to
our understanding of serotonin signaling.
Although voltammetric studies of serotonin have used a wide
array of stimulation parameters, one type has been used repeat-
edly in the studies reviewed in this article. Pseudo-one-pulse
(POP) stimulations consist of 5–10 pulses applied at 100–200Hz
and are shorter than 100ms in duration. They are designed to
approximate a single electrical impulse but evoke more con-
sistent efflux. In brain slice experiments, POP stimulations are
often used to avoid creating an endogenous “tone” at receptors,
which facilitates more direct investigation of selective agonists
and antagonist’s effects on autoreceptor-mediated modulation of
release (Limberger et al., 1991; Thienprasert and Singer, 1993).
Endogenous serotonin concentrations have been evoked
in vivo using electrical stimulation of the DRN as well as the
medial forebrain bundle (MFB). A subset of serotonergic neu-
rons that project to the SNr also send axon collaterals to fore-
brain structures via the MFB (Van Der Kooy and Hattori, 1980).
Electrical stimulation of these collaterals excites SNr-projecting
neurons in a retrograde direction, eliciting serotonin in the
desired region (Hashemi et al., 2011). While targeting a stim-
ulation electrode to the MFB is less challenging than targeting
the DRN, this stimulation site can also be used to evoke neu-
rotransmitter release in many brain regions. This may have
indirect effects on serotonin signaling, complicating interpreta-
tion of data. Many optimal stimulation parameters are consistent
between in vitro and in vivomeasurements, including pulse width,
stimulation intensity, and stimulation length. However, the con-
centration of serotonin evoked in the SNr is remarkably lower
than predicted by brain slice measurements, prompting curiosity
about the potential for serotonergic regulatory mechanisms that
require intact brain tissue.
RELEASE
Local electrical stimulations of serotonin terminals in brain
slices typically evoke concentration changes in the 100 nM range.
In vivo, however, serotonin concentrations evoked in the SNr
rarely reach 100 nM, even after pharmacological manipulations
(Hashemi et al., 2012). In vivo serotonin release, measured in
an intact brain, is presumably limited by negative feedback from
somatodendritic and terminal autoreceptors as well as inhibitory
neurotransmitters that are released concurrently, which may
account for some of the disparity in release amplitudes. In brain
slices, concentration flux coincides with onset of the stimulation
pulse train and this rising phase reaches its maximumwithin mil-
liseconds of the stimulation’s end. Serotonin evoked in vivo tends
to overshoot the duration of stimulation. The overshoot is par-
tially an effect of the broader area of release sites activated by a
remote stimulation location, but is also due to limited diffusion
rates through a Nafion polymer coating that is applied to enhance
sensitivity in vivo (Hashemi et al., 2009).
As mentioned in a previous section, electrically-evoked sero-
tonin concentrations measured in brain slices are sensitive to
stimulation frequency. A proposal by Wightman et al. (1988)
explains this observation: more uptake occurs in the time
between stimulation pulses during low frequency stimulations,
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which limits the summation of extracellular neurotransmitter
concentration (Wightman et al., 1988). Jennings et al. (2010)
hypothesized that shifts in uptake rate associated with differen-
tial serotonin transporter expression would predictably alter this
frequency dependence. Mice with either gain or loss of SERT
expression both displayed significantly lower sensitivity to stim-
ulation frequency than their wild-type littermates. Furthermore,
in wild-type mice, a selective serotonin transporter inhibitor
reduced sensitivity to stimulation frequency (Jennings et al.,
2010). These findings underscore the importance of SERT in
establishing a functional, dynamic equilibrium between release
and uptake that enables coherent serotonin signaling.
Time-resolved measurements with FSCV also enable exami-
nation and comparison of the kinetic parameters of serotonin
transmission. Neurotransmitter uptake is assumed to follow
Michaelis–Menten dynamics, and uptake as well as concentra-
tion evoked per stimulus pulse can be calculated using a modified
model of enzyme kinetics. Figure 3 shows the equations used
to model (i) uptake and (ii) release and representative signals
predicted for stimulations of varying frequency. In brain slice
preparations, the concentration evoked per stimulation pulse
([5-HT]pulse) was found to be 100± 20 nM in DRN, and signifi-
cantly lower in the SNr, at 55± 7 nM. Differences in [5-HT]pulse
are proportional to differences in tissue content between the
two brain regions, indicating that local stores of serotonin may
influence the concentration that can be evoked by electrical stim-
ulation (Bunin et al., 1998). In vivo [5-HT]pulse in the SNr is
much lower, comparatively: 1.5 nM per pulse using DRN stim-
ulation, and 1.1 nM per pulse from the MFB. Figure 4 shows an
averaged recording of in vivo serotonin signals in the SNr; note
that the concentration evoked is strikingly lower than predicted
by the model in Figure 3. Given that both Bunin et al. (1998)
and Hashemi et al. (2011) conducted experiments in the SNr, the
nearly 50-fold difference cannot be attributed to differences in
tissue content. Instead, this discrepancy between brain slice and
in vivo preparations suggests powerful regulatory mechanisms
acting on serotonin release in vivo which may depend on intact
circuitry.
Hashemi et al. (2012) investigated mechanisms that may limit
in vivo neurotransmission by using a common MFB stimulation
to compare serotonin and dopamine efflux in the SNr and nucleus
accumbens, respectively. The dopamine system serves as a good
basis for comparison with the serotonin system because the two
monoamines share parallel features in the mechanisms control-
ling their synthesis, release, modulation, uptake, and metabolic
degradation. Inhibition of the monoamine synthesis enzyme
aromatic amino acid decarboxylase and monoamine vesicular
packing protein (VMAT2) considerably decreased the concentra-
tion of evoked dopamine to 18% and 6% of control amplitudes,
respectively, but affected serotonin to a much lesser extent (48%
and 72%, respectively). Serotonin efflux was also resistant to
short term depression after repeated stimulation pulse trains,
while dopamine efflux was attenuated by 38% after 20 stimu-
lations. This suggests that a relatively small proportion of the
available vesicular serotonin is mobilized for release by each elec-
trical stimulation train, a finding which may partially explain the
low concentrations observed in vivo.
FIGURE 3 | A model predicts serotonin release and uptake at different
frequencies. Top panel: Equation (i) describes rate of uptake (v) as a
function of maximal uptake rate (Vmax), the Michaelis constant for SERT
(KM ), and concentration of released serotonin ([5-HT]). Equation (ii)
describes the expected concentration of released serotonin given a
stimulation with number of pulses (p) and frequency (f ), less the uptake
that occurs over this time period. Lower panel: Concentration evoked by
50 pulse stimulation trains at 100, 20, and 10Hz, as predicted by the model.
Traces are representations of data based on Bunin et al. (1998).
MODULATION BY AUTORECEPTORS
Three subtypes of serotonin receptors, all 5-HT1-type, are
expressed on serotonergic axons, soma, and dendrites and
function as autoreceptors that provide inhibitory feedback.
5-HT1-type receptors are found throughout the brain as autore-
ceptors, expressed on pre-synaptic serotonin terminals, and also
as heteroreceptors, expressed on post-synaptic targets. The most
well-studied autoreceptors, 5-HT1A, 1B, and 1D are seven trans-
membrane, G-protein coupled receptors (GPCRs). 5-HT1B and
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FIGURE 4 | Sample trace of in vivo serotonin release and uptake.
Release was elicited using 60 pulses, 60Hz, 325µA stimulation of the DRN
and recorded in mouse SNr. Average of signals from 7 subjects.
1D autoreceptors negatively couple to adenylyl cyclase (Yocca and
Maayani, 1990). 5-HT1A heteroreceptors throughout the brain
also inhibit adenylyl cyclase activity, but autoreceptors in theDRN
apparently function through a different Gi-coupled mechanism
(Clarke et al., 1996). In vivo studies of these autoreceptors are
challenging because even highly-selective drugs inadvertently tar-
get pharmacologically-identical heterosynaptic receptors, which
are often expressed at high levels in the same brain region as the
autoreceptor. Intact circuitry thus makes it difficult to extricate
direct effects of autoreceptor activity from indirect regulation by
heteroreceptors.
Voltammetric measurements in brain slices avoid some of the
problems associated with 5-HT1-type receptor pharmacology. In
slices, the absence of spontaneous activity in serotonergic cells,
due to either separation from cell bodies in a terminal slice or
elimination of noradrenergic inputs in a DRN slice, results in
loss of endogenous serotonin tone (Judge and Gartside, 2006).
Therefore, these experiments avoid tonic activation of autore-
ceptors and can also avoid transient autoreceptor activity, when
appropriate, using POP stimulations. This provides an oppor-
tunity to study the timing and function of these receptors in
relative isolation. O’Connor and Kruk (1991b) showed that the
non-selective autoreceptor antagonist methiothepin did not affect
the concentration of serotonin evoked by POP stimulations,
but increased serotonin elicited by longer stimulations. Further
exploration with stimulations of varying frequency and duration
determined that activation of autoreceptors requires a stimula-
tion period of at least 400ms (O’Connor and Kruk, 1991b). This
time frame is comparable to the activation window for dopamine
autoreceptors in striatal and limbic regions. Phillips et al. (2002)
found that the activation delay observed for dopamine autore-
ceptors reflects timing of intracellular cascades added to the rate
of neurotransmitter diffusion in a given brain area (Phillips et al.,
2002).
5-HT1A, 1B, and 1D receptors are expressed at high levels in
the DRN, where they negatively influence neuronal firing rate
and extracellular levels of serotonin (Sprouse and Aghajanian,
1987; Pineyro et al., 1995; Moret and Briley, 1997; Adell et al.,
2001). Voltammetric studies corroborate the inhibitory functions
of all three receptors in this region by demonstrating that their
selective agonists can reduce the amplitude of electrically-evoked
serotonin release (Davidson and Stamford, 1995b; Hopwood
and Stamford, 2001). Although its heteroreceptor analogues are
prominently expressed in limbic regions, 5-HT1A autorecep-
tors are only expressed in the DRN and median raphe nucleus
(Verge et al., 1985). Serotonin levels in forebrain terminal regions
are affected by 5-HT1A-mediated changes in DRN unit activ-
ity (Kreiss and Lucki, 1994; Casanovas et al., 1997), but only
5-HT1B and 1D autoreceptors are expressed locally to function-
ally inhibit release in these regions. Voltammetric measurements
in the SCN and vLGN confirm absence of 5-HT1A autorecep-
tor function in these terminal regions. 5-HT1B and 1D receptors,
and not 5-HT1A receptors, negatively influence serotonin efflux
in brain slices containing terminal regions (O’Connor and Kruk,
1992; Davidson and Stamford, 1996).
The 5-HT1A receptor may be the trump card in this fam-
ily of autoreceptors: 5-HT1A receptor mRNA is expressed in
nearly 100% of serotonergic cells and up to 15% of GABAergic
interneurons in the DRN (Day et al., 2004). This receptor robustly
regulates both neuronal firing rates and extracellular serotonin
levels in the DRN (Sprouse and Aghajanian, 1987; Hjorth and
Sharp, 1991). Voltammetric measurements find that antagonists
for 5-HT1A and 1B have a supra-additive effect when adminis-
tered together: increase in serotonin efflux is greater when both
receptors are blocked than would be expected given the effect of
each antagonist alone (Roberts and Price, 2001). In addition, the
effects of 5-HT1B receptor antagonists on serotonin efflux are
overpowered by 5-HT1A receptors unless they are also blocked,
suggesting that these receptors compensate for reductions of
5-HT1B activity. Given these results, it is suggested that 5-HT1A
and 1B receptors exhibit a functional interaction that is facili-
tated by proximal expression sites on serotonin neurons. Interest
in 5-HT1A receptors has increased in the last decade, as they may
play a role in depression and anxiety-related disorders (Ohno,
2010). Use of FSCV in future studies could meaningfully con-
tribute to our understanding of how 5-HT1A receptor-mediated
modulation of serotonin release plays a role in the etiology and
treatment of these disorders.
Much speculation has occurred regarding the explanation for
seemingly parallel functions of 5-HT1B and 1D autoreceptors.
Both receptors are expressed in most serotonergic brain regions
and have superficially redundant effects. One theory posits that
these autoreceptors differ in their affinity for serotonin: one high
affinity and the other low affinity. However, it has since been
demonstrated that their affinities are nearly identical (Boess and
Martin, 1994). More likely, the two receptors are expressed in
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different anatomical locations, and thus provide site-specific reg-
ulation of serotonin release, e.g., dendritic vs. axonal localizations
in the DRN. Stamford et al. (2000) have reviewed the evidence
supporting this hypothesis (Stamford et al., 2000).
The SNr expresses the highest concentration of 5-HT1B
autoreceptors and heteroreceptors in the murine brain (Pazos
and Palacios, 1985). 5,7-HT-induced lesions of serotonin neu-
rons reduced 5-HT1B expression level by 37%, presumably due
to degradation of serotonin terminals (Verge et al., 1986); this
suggests that over 1/3 of 5-HT1B receptors expressed in the
SNr could function as autoreceptors. Heterosynaptic function
of 5-HT1B receptors on presynaptic sites in the SNr has been
well-documented and may yield important therapeutic findings
(Sari, 2004), but its functionality as an autoreceptor in the SNr
remains controversial. Iravani and Kruk (1997) found no effects
of 5-HT1B receptor antagonists on electrically-evoked serotonin
concentrations in SNr slice preparations (Iravani and Kruk,
1997). However, Threlfell et al. (2010) report that these autore-
ceptors influence short-term depression of serotonin efflux. In
paired stimulation trains, the concentration of serotonin evoked
by the second stimulation (S2) reached 30% of that evoked
by the first stimulation (S1) when there was a 1 second delay
between S1 and S2. Antagonists of 5-HT1B receptors relieved
this depression by up to 20% (Threlfell et al., 2010). 5-HT1B
autoreceptors are thus apparently functional in the SNr, although
their modulatory effects may be less robust than in other brain
regions.
It is possible that the role of autoreceptors could be better elu-
cidated by in vivo voltammetric studies, where endogenous sero-
tonin tone is undisturbed and autoreceptor function is closer to
normal physiological levels. However, a limited number of studies
currently address the effects of serotonin’s autoreceptors in vivo.
In practice, it is difficult to selectively target 5-HT1-type recep-
tors on serotonin terminals when pharmacologically indistinct
5-HT1-type heteroreceptors are expressed throughout the brain.
As with in vivo microdialysis, the direct roles of the autorecep-
tor would be difficult to extricate from indirect modulation by in
situ circuitry. Recent technological advancements in iontophore-
sis enable spatially-resolved, quantitative drug delivery at the
site of voltammetric measurements (Herr and Wightman, 2013).
Future studies using FSCV combined with this drug-delivery
method have great potential to answer important questions about
serotonin’s autoreceptors.
UPTAKE
Serotonin clearance is achieved primarily via active transport.
Its transporter, SERT, is a member of the Na+/Cl− transporter
family, which includes dopamine, norepinephrine, GABA, and
glutamate transporters (Bennett et al., 1973; Iversen, 1974). SERT
displays high affinity for serotonin in the nanomolar concen-
tration range (Blakely et al., 1991). Inhibitors of SERT, selective
serotonin reuptake inhibitors (SSRIs), have been a significant tar-
get of research efforts for decades, owing to their widespread
use as antidepressant medications. Given acutely, SSRIs exert
striking effects on the serotonin system: they elevate extra-
cellular serotonin levels in the DRN (Bel and Artigas, 1992),
which in turn decreases rate of cell firing due to activation of
5-HT1A autoreceptors (Chaput et al., 1986; Gartside et al., 1995).
However, in therapeutic practice, SSRIs relieve depressive symp-
toms only after a chronic period of 3–6 weeks. It is during
this period that the effects of transport inhibition on serotonin
transmission become less clear. FSCV provides an ideal method
for deciphering the effects of SSRIs because it can distinguish
between changes in released serotonin and changes in rate of
uptake.
Electrically-evoked changes in serotonin concentration are
cleared from the extrasynaptic space within seconds of stimula-
tion termination. The term t1/2 is often used to compare rates
of clearance; t1/2 is the time elapsed between peak concentration
of neurotransmitter and its decay to half this amplitude. Across
brain regions, brain slice and in vivo voltammetric measurements
report similar values of t1/2 ranging from approximately 1 to 3
seconds (O’Connor and Kruk, 1994; Iravani et al., 1999; Davidson
and Stamford, 2000; Hashemi et al., 2012). Rates of neurotrans-
mitter clearance may positively correlate with the density of
transporter sites in a given brain region: Bunin et al. (1998) report
clearance rates of 1300± 20 nM/s in the DRN and 570± 70 nM/s
in the SNr, and quantitative autoradiographic studies report 2–4-
fold greater SERT binding levels in the DRN (Kovachich et al.,
1988; Kovacevic et al., 2010). However, some comparisons of
SERT density across brain regions do not support this conclu-
sion, particularly in species other than rat, so more thorough
investigation of the relationship between transporter expression
and SERT density is needed. In addition to influencing uptake
rate, brain slice studies in mice that either lack or overexpress
SERT have demonstrated a negative correlation between trans-
porter expression level and concentration of serotonin evoked by
electrical stimulation (John et al., 2006; Jennings et al., 2010). The
disparity observed between clearance rates in the DRN and SNR
is conspicuously proportional to differences Bunin et al. (1998)
reported in release rates. This suggests a consistent relationship
between transporter expression levels, uptake rates, and release
rate. Modeling serotonin signaling kinetics in more brain regions
could confirm whether this relationship holds true throughout
the brain.
SSRIs decrease rate of neurotransmitter clearance while
increasing the maximum amplitude of electrically-evoked sero-
tonin concentrations. In brain slices, SERT inhibition slows clear-
ance (measured as an increase in t1/2) by 150–700%. This wide
spread of responses may be attributable to experimental vari-
ability between studies, particularly differences in stimulation
parameters. Indeed, in vivo studies of SSRI effects in the SNr using
identical stimulation parameters report comparable changes in
t1/2 using MFB and DRN stimulation sites (increasing by 324
and 306%, respectively) (Hashemi et al., 2009, 2012). SSRIs also
increase evoked serotonin concentrations by 200–450% in SNr
brain slices, and up to 410% in vivo (Iravani et al., 1999; John
et al., 2006; Hashemi et al., 2012). In this case, the intensity of the
SSRI’s effect is associated with different stimulation frequencies or
pulse number. Structure and selectivity differences between SERT
inhibitors may also contribute to variable responses between
voltammetric studies; however, differences between SSRIs have
not been specifically investigated using FSCV. Serotonin efflux in
SNr brain slices has been modeled to describe the effects of an
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SSRI, fluoxetine, on apparentKM , theMichaelis–Menten constant
(John et al., 2006). Quantifying changes toKM ,Vmax and [5-HT]p
may be amore effective way to contrast the effects of various SERT
inhibitors on serotonin signaling in future studies in brain slices
and in vivo. Thorough comparison of these effects could inform
clinical usage of these pharmacotherapies.
AUTORECEPTORS MEDIATE SOME EFFECTS OF ACUTE UPTAKE
INHIBITION
In addition to their inhibitory influence on release, serotonin’s
autoreceptors appear to modulate response to SERT inhibition.
A number of studies report that autoreceptor antagonists can
potentiate the rise in extracellular serotonin levels elicited by
SSRIs (Hjorth, 1993; Artigas et al., 1994), and 5-HT1A autore-
ceptors also mediate reduction of firing rate by SSRIs in the
DRN (Gartside et al., 1995). The concentration change evoked by
POP stimulations, deliberately rapid enough to avoid creating an
endogenous tone, typically does not activate autoreceptors and is
thus not affected by their antagonists. However, in brain slices of
the DRN, paroxetine-induced increases in serotonin efflux were
potentiated by 5-HT1A and 1B/D receptor antagonists (Davidson
and Stamford, 1995a). Therefore, it is hypothesized that SERT
inhibition causes an increase in extracellular serotonin levels suffi-
cient to activate autoreceptors, even in brain slices. This produces
an inhibitory tone, such that autoreceptor antagonists can fur-
ther unmask SSRI-induced increases in release. 5-HT1B and 1D
autoreceptors appear to similarly potentiate the effects of SSRIs
in distal brain regions, as the Stamford lab also reports increases
in paroxetine’s effects in the vLGN when co-administered with
5-HT1B and 1D receptor antagonists (Davidson and Stamford,
1997). The interaction between regulation of release and uptake
functions may also be an important detail in understanding
how chronic uptake inhibition functions in treating depressive
disorders.
CHRONIC UPTAKE INHIBITION
The gap between onset of acute physiological effects and the ther-
apeutic efficacy achieved in a chronic treatment period implies
that SSRI-induced increases in serotonin levels are not directly
producing antidepressant effects. Instead, elevated serotonin lev-
els may influence long-term changes in serotonin signaling and
its downstream targets to relieve symptoms of depression (Blier
et al., 1987). The effects of long-term SERT inhibition are con-
flicting: some find increases in extracellular serotonin levels, and
some find no changes. Associated with these outcomes are vari-
able reports of autoreceptor desensitization or hypersensitization
of 5-HT1A and 1B autoreceptors (Chaput et al., 1986; Invernizzi
et al., 1992, 1995; Bosker et al., 1995a,b; Moret and Briley, 1996).
Studies examining the effects of chronic SSRI treatment using
FSCV have produced more consistent findings.
FSCV measurements of serotonin signaling after 21 days of
SSRI exposure reveal that rate of clearance, measured by t1/2, is
unchanged by this treatment. This lack of change is intriguing
because radioligand binding studies report brain-wide reductions
in SERT density after chronic inhibition (Kovacevic et al., 2010).
It may reflect compensation by other clearance mechanisms,
such as low affinity serotonin transporters. High and low affinity
transport systems have been described for other monoamine
neurotransmitters (Iversen, 1974; Stamford et al., 1984, 1990;
Hagan et al., 2011). Although studies suggest that these trans-
porters may play an important role in serotonin signaling (Daws,
2009), there are presently no FSCV studies describing their role in
modulating release and uptake. The role of non-selective uptake
transporters in modulating serotonin signaling, particularly fol-
lowing chronic SSRI treatment, would be interesting to investigate
using FSCV.
Long-term SSRI treatment increases stimulation-evoked sero-
tonin concentrations in the DRN and other brain regions by
20–100%, depending on the experiment and brain region stud-
ied (O’Connor and Kruk, 1994; Davidson and Stamford, 1998,
2000).These findings concur with the results of Schoups et al.
(1986), who found that electrically-evoked release of tritiated
serotonin (3[H]5-HT) in the hypothalamus increased after 21
days of SSRI treatment (Schoups et al., 1986). Although increases
in serotonin efflux are observed after acute SERT inhibition, these
can be explained by changes in rate of uptake. However, t1/2
was not altered in any voltammetric investigation of long-term
SSRI treatment. Therefore, increases in evoked concentrations
induced by chronic treatment must rely on another mecha-
nism. Changes in other aspects of release may contribute to
this effect, for example: the quantity or composition of sero-
tonin stored in vesicles, regulation of intracellular calcium, or
excitability of the synaptic membrane. In-depth exploration of
these mechanisms has not yet been explored using voltammetric
methods.
Alterations in 5-HT1A autoreceptors contribute to the effects
of chronic SSRIs on serotonin signaling. Under normal condi-
tions, activated 5-HT1A receptors inhibit serotonin release and
neuronal firing rates, and chronic SSRI treatment may modify
this activity. Selective suppression of 5-HT1A autoreceptors can
produce antidepressant behavioral effects in the absence of SSRIs
(Bortolozzi et al., 2012). Many investigations have described func-
tional desensitization of 5-HT1A receptors after chronic SERT
inhibition, but to varying degrees across brain regions (Kreiss
and Lucki, 1994, 1997; Cremers et al., 2000; Bosker et al., 2001;
Rossi et al., 2008). Davidson and Stamford (1998) compared sero-
tonin release and uptake and neuronal firing rates in the DRN
of rats treated with water or paroxetine for 21 days. Paroxetine-
treated rats had significantly higher serotonin release rates but
exhibited no differences in firing rate. Interestingly, application
of a 5-HT1A receptor agonist revealed that firing rate was less
sensitive, and release amplitude more sensitive, to this manipu-
lation. Contradictory findings of 5-HT1A receptor sensitivity was
not a total surprise: prior studies found similar desensitization
of 5-HT1A receptors in the control of firing rate after chronic
paroxetine treatment (Chaput et al., 1986; Blier et al., 1988, 1990),
and O’Connor and Kruk (1994) had previously reported sensi-
tization of 5-HT1A receptors controlling release amplitude. The
dichotomous effect of chronic SSRIs on 5-HT1A receptor sensi-
tization indicates a functional distinction between the receptors
mediating neuronal firing and those controlling release. Given
the complex effects of chronic SSRIs on 5-HT1A autoreceptors in
the DRN, it would be interesting to see how these changes trans-
late to serotonin release in an intact brain. Currently, however, no
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studies employing FSCV have examined the effects chronic SERT
inhibition in vivo.
5-HT1B and 1D receptors also desensitize after chronic SERT
inhibition, although the extent to which this occurs appears to
vary between brain regions. O’Connor and Kruk (1994) reported
desensitization of 5-HT1B receptors in SCN after chronic treat-
ment with fluoxetine. In contrast, the Stamford lab found no
changes in the sensitivity of 5-HT1B receptors in the vLGN,
instead finding desensitization of 5-HT1D receptors after chronic
paroxetine. This inconsistency may reflect differences in autore-
ceptor expression in the SCN and vLGN, or result from difficulty
in selectively targeting the 5-HT1B receptor pharmacologically
(O’Connor and Kruk do not address the effects of 5-HT1D recep-
tors in their study). Additionally, while O’Connor and Kruk
(1994) found no desensitization of 5-HT1B receptors in the
DRN, Davidson and Stamford (2000) later demonstrated that
5-HT1B receptor desensitization was apparent only when the
5-HT1A autoreceptor is antagonized (Davidson and Stamford,
2000). This adds further weight to the conjecture that 5-HT1A
and 1B receptors functionally interact in the DRN.
MONOAMINE OXIDASE
Metabolic degradation of serotonin by the enzyme MAO also
contributes to serotonin clearance, especially in the developing
brain (Cases et al., 1995, 1998). However, MAO inhibition in
brain slices has no reported effect on release amplitudes or uptake
(O’Connor and Kruk, 1991a), a finding used to confirm absence
of serotonin’s metabolites from the voltammetric signal. Owesson
et al. (2002) showed a greater role ofMAO in regulating serotonin
efflux using transgenic mice lacking MAO-A expression. MAO-
A is the isoenzyme that preferentially degrades norepinephrine,
epinephrine, dopamine, and serotonin, and mice lacking this
enzyme have decreased neuronal firing rates in the DRN and
increased extracellular serotonin levels (Evrard et al., 2002). In
brain slices of the DRN, MAO-A-deficient mice displayed sig-
nificantly greater serotonin efflux and reduced clearance rates
compared to wild-type controls. Additionally, the effects of citalo-
pram were smaller and radioligand binding showed significantly
lower expression of SERT in these mice (Owesson et al., 2002).
This suggests that serotonin signaling is subject to regulation by
MAO under the right experimental conditions. In vivo work sup-
ports this idea, as a recent study has shown that MAO inhibitors
dramatically increase serotonin efflux in the SNr (Hashemi et al.,
2012). MAO inhibition also has a much greater effect on sero-
tonin than dopamine efflux when compared in vivo, suggest-
ing a unique role for metabolic degradation in the regulation
of serotonin transmission compared to other monoaminergic
systems.
FUTURE DIRECTIONS
Most of the studies reviewed in this article focused on describing
the role of autoreceptors and transporters in modulating sero-
tonin signaling throughout the brain. However, signaling is also
considerably influenced by many other neurotransmitter systems,
including norepinephrine, glutamate, GABA, and a number of
neuroendocrine modulators. These external influences are highly
implicated in serotonin’s involvement in a number of psychiatric
disorders and, while they have been investigated by other tech-
niques, their functions have not been fully described using sub-
second voltammetric measurements. Evaluating the effects of
external modulatory mechanisms on the subsecond dynamics of
serotonin signaling could provide important clues about their role
in neurological disorders.
Ongoing methodological developments continue to progress
voltammetric measurements beyond the current experimental
limits. While electrochemical techniques have been optimized
for serotonin detection (Lama et al., 2012), multi-electrode
arrays are being developed which would enable measurements
of multiple neurotransmitters in multiple locations simultane-
ously. Additionally, iontophoretic methods adapted for FSCV
now enable localized, quantitative drug delivery, enabling inves-
tigation of recording-site specific effects in vivo. FSCV can also
be paired with concurrent electrophysiological measurements to
couple information about neurotransmitter release to single-unit
responses of post-synaptic neurons. Iontophoretic and electro-
physiological methods have already been applied to voltammetric
studies of dopamine release in anaesthetized and freely-moving
animals (Takmakov et al., 2011), and the Wightman group is
currently working to adapt these methods for serotonin detection.
It has previously been challenging to selectively study sero-
tonin’s autoreceptors in vivo because homologous receptors are
expressed throughout the brain. However, many novel drug-
delivery and transgenic methods have been developed to avoid
this type of complication. DREADDs, designer receptors with
exogenous ligands, have been used to target specific G-protein-
activated cascades in serotonergic neurons (Dong et al., 2010). A
light-activated 5-HT1A receptor has been generated that can be
expressed selectively on serotonergic neurons (Oh et al., 2010).
Furthermore, transgenic mice and rats offer many opportuni-
ties to study signaling in models of neurological disorders and
targeted deletions. The effects of SERT deletion or overexpres-
sion on serotonin signaling have been investigated in brain slices
of the SNr but not in an in vivo preparation. Many conditional
knockout mouse models, which avoid confounding develop-
mental effects, are now available for serotonin’s transporter and
receptors. These techniques could lead to more selective tar-
geting and better characterization of serotonin’s receptors and
their downstream effectors in combination with voltammetric
measurements.
Voltammetric measurements have, until recently, been limited
to brain regions with high levels of the neurotransmitter of inter-
est and limited presence of other electroactive compounds. This
is because electrical stimulations indiscriminately excite all prox-
imal nerve terminals. Use of optogenetic stimulation circumvents
this barrier by enabling selective excitation of a specific popula-
tion of neurons. Channelrhodopsin-2-mediated serotonin efflux
has been measured in fly larvae using FSCV in a technique devel-
oped by the Venton group. The light-evoked efflux is vesicular and
subject to regulation by synthesis and uptake transport in a man-
ner that is similar to mammalian serotonin release (Borue et al.,
2009, 2010). Selective stimulation of serotonergic neurons in a
mammalian model would permit measurements in brain regions
with significant interference from other electroactive neurotrans-
mitters, such as the hippocampus.
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FIGURE 5 | A synopsis of the findings presented in this article. Serotonin
(5-HT) is synthesized from tryptophan in a two-step process requiring
tryptophan hydroxylase and aromatic amino acid decarboxylase. Serotonin is
packaged into vesicles by vesicular monoamine transporter 2 (VMAT2) and is
released via calcium-dependent exocytosis. Released serotonin diffuses to
extrasynaptic receptors and transporters via volume transmission. Its
autoreceptors (5-HT1A, 1B, and 1D) are inhibitory and coupled to Gi proteins.
The serotonin transporter (Thienprasert and Singer) has high affinity and
selectivity for uptake of extracellular serotonin. Inside the terminal, serotonin
is primarily metabolized by monoamine oxidase (MAO).
Finally, while voltammetric measurements of serotonin have
presently only occurred in brain slices and anaesthetized animals,
an exciting future direction for research will be monitoring
serotonin signaling in an awake, freely moving animal. FSCV
has been used to measure endogenous dopamine and nore-
pinephrine release in freely moving animals, and this research
has led to groundbreaking information coupling real-time neu-
rotransmission to specific facets of behaviors. Many ques-
tions remain about serotonin’s role in both basic and complex
nervous system processes, and coupling FSCV to relevant
behavioral paradigms may yield important clues about its
function.
CONCLUSION
Serotonin signaling is an important component in the etiology
and treatment of many neurological disorders. By combining
subsecond temporal resolution with nanomolar sensitivity to
concentration changes, FSCV has revealed a great deal about
dynamic serotonin transmission. These findings are summarized
by the illustration in Figure 5. Studies using voltammetric meth-
ods have emphasized the importance of autoreceptor-mediated
inhibitory feedback mechanisms in normal signaling as well as
response to SSRIs. Further, recent in vivo measurements suggest
that intact brain circuitry supports the involvement of multiple
modulatory mechanisms in the control of serotonin signaling.
New developments in a variety of techniques present potential for
more intricate assessment of regulation within and external to the
serotonin system. Future studies using FSCV in combination with
new technologies will likely elucidate many of the mysteries of the
serotonin system.
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